JP2010501476A - 副甲状腺ホルモン類似体およびその使用方法 - Google Patents

副甲状腺ホルモン類似体およびその使用方法 Download PDF

Info

Publication number
JP2010501476A
JP2010501476A JP2009522751A JP2009522751A JP2010501476A JP 2010501476 A JP2010501476 A JP 2010501476A JP 2009522751 A JP2009522751 A JP 2009522751A JP 2009522751 A JP2009522751 A JP 2009522751A JP 2010501476 A JP2010501476 A JP 2010501476A
Authority
JP
Japan
Prior art keywords
pth
bone
dose
administration
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009522751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501476A5 (fr
Inventor
ポール モーリー，
マーティン ストグニュー，
ブライアン マクドナルド，
ジーン スコット メルトカ，
ナゲシュ アール． パレプ，
Original Assignee
ゼロス セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/517,146 external-priority patent/US20070099831A1/en
Priority claimed from US11/650,918 external-priority patent/US20070270341A1/en
Application filed by ゼロス セラピューティクス， インコーポレイテッド filed Critical ゼロス セラピューティクス， インコーポレイテッド
Publication of JP2010501476A publication Critical patent/JP2010501476A/ja
Publication of JP2010501476A5 publication Critical patent/JP2010501476A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2009522751A 2006-07-31 2007-05-02 副甲状腺ホルモン類似体およびその使用方法 Pending JP2010501476A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US83498006P 2006-07-31 2006-07-31
US83797206P 2006-08-15 2006-08-15
US11/517,146 US20070099831A1 (en) 2005-09-06 2006-09-06 Parathyroid hormone analogues and methods of use
US11/650,918 US20070270341A1 (en) 2005-09-06 2007-01-05 Parathyroid hormone analogues and methods of use
US90569307P 2007-03-07 2007-03-07
US92563907P 2007-04-20 2007-04-20
PCT/US2007/010720 WO2008016404A2 (fr) 2006-07-31 2007-05-02 Analogues de l'hormone parathyroïdienne et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
JP2010501476A true JP2010501476A (ja) 2010-01-21
JP2010501476A5 JP2010501476A5 (fr) 2010-06-17

Family

ID=56290957

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009522751A Pending JP2010501476A (ja) 2006-07-31 2007-05-02 副甲状腺ホルモン類似体およびその使用方法

Country Status (4)

Country Link
EP (1) EP2056862A2 (fr)
JP (1) JP2010501476A (fr)
CA (1) CA2659846A1 (fr)
WO (1) WO2008016404A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019059302A1 (fr) * 2017-09-22 2019-03-28 旭化成ファーマ株式会社 Composition pharmaceutique liquide contenant du tériparatide ayant une excellente stabilité
JP2021167354A (ja) * 2017-09-22 2021-10-21 旭化成ファーマ株式会社 薬物動態及び／又は安全性に優れるテリパラチド含有液状医薬組成物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011001273A (ja) * 2009-06-16 2011-01-06 Eci Inc ｅＭＩＰを有効成分とする水溶性製剤
WO2014118705A1 (fr) * 2013-01-31 2014-08-07 Novartis Ag Procédé de traitement des troubles minéraux et osseux de la maladie rénale chronique en utilisant des antagonistes de la sclérostine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500845A (ja) * 1996-08-02 2001-01-23 ナショナル リサーチ カウンシル オブ カナダ 骨粗鬆症の治寮のための副甲状腺ホルモン類似体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2126299C (fr) * 1994-06-20 2000-12-12 Gordon E. Willick Analogues de l'hormone parathyroidienne utilises pour le traitement de l'osteoporose
US5955425A (en) * 1996-08-02 1999-09-21 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US6110892A (en) * 1994-06-20 2000-08-29 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US6316410B1 (en) * 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
ITMI20041440A1 (it) * 2004-07-19 2004-10-19 Abiogen Pharma Spa Peptidi analoghi del pth-1-11

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500845A (ja) * 1996-08-02 2001-01-23 ナショナル リサーチ カウンシル オブ カナダ 骨粗鬆症の治寮のための副甲状腺ホルモン類似体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN7012001538; Ｃｕｒｒｅｎｔ　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｄｅｓｉｇｎ Ｖｏｌ．７, 2001, ｐ．６７１-６８７ *
JPN7012001539; Ｃｕｒｒｅｎｔ　Ｏｐｉｎｉｏｎ　Ｉｎ　Ｉｎｖｅｓｔｉｇａｔｉｏｎａｌ　Ｄｒｕｇｓ Ｖｏｌ．７，　Ｎｏ．４, 20060401, ｐ．３４９-３５９ *
JPN7012001540; Ｄｒｕｇｓ　ｏｆ　Ｔｏｄａｙ Ｖｏｌ．４０，　Ｎｏ．１１, 2004, ｐ．９３５-９４８ *
JPN7012001541; Ｊｏｕｒｎａｌ　ｏｆ　Ｂｏｎｅ　ａｎｄ　Ｍｉｎｅｒａｌ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．１２，　Ｎｏ．８, 1997, １２４６-１２５２ *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019059302A1 (fr) * 2017-09-22 2019-03-28 旭化成ファーマ株式会社 Composition pharmaceutique liquide contenant du tériparatide ayant une excellente stabilité
JP2019073543A (ja) * 2017-09-22 2019-05-16 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
JP2019089865A (ja) * 2017-09-22 2019-06-13 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
JP2019089864A (ja) * 2017-09-22 2019-06-13 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
JPWO2019059302A1 (ja) * 2017-09-22 2019-11-14 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
JP2020040995A (ja) * 2017-09-22 2020-03-19 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
JP2020114843A (ja) * 2017-09-22 2020-07-30 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
JP2021036000A (ja) * 2017-09-22 2021-03-04 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
JP2021167354A (ja) * 2017-09-22 2021-10-21 旭化成ファーマ株式会社 薬物動態及び／又は安全性に優れるテリパラチド含有液状医薬組成物

Also Published As

Publication number Publication date
CA2659846A1 (fr) 2008-02-07
EP2056862A2 (fr) 2009-05-13
WO2008016404A2 (fr) 2008-02-07
WO2008016404A3 (fr) 2009-01-15

Similar Documents

Publication Publication Date Title
US20070099831A1 (en) Parathyroid hormone analogues and methods of use
US7384912B2 (en) Treatment of bone disorders with skeletal anabolic drugs
KR100679778B1 (ko) PTHrP 유사체를 사용하는 골절 치료법
US20070270341A1 (en) Parathyroid hormone analogues and methods of use
JP6522715B2 (ja) １回当たり１００〜２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤
US20080176787A1 (en) Parathyroid hormone analogues and methods of use
WO2011139838A2 (fr) Formulations intranasales
JP2010501476A (ja) 副甲状腺ホルモン類似体およびその使用方法
US20090010940A1 (en) Parathyroid Hormone Analogues and Methods of Use
US20090042774A1 (en) Parathyroid hormone analogues and methods of use
MX2007003185A (es) Tratamiento de trastornos oseos con farmacos anabolicos esqueletales.

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100420

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120424

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121105